{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Haddad A"],"funding":["CCR NIH HHS","NCI NIH HHS"],"pagination":["1021-1032"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11773633"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["32(2)"],"pubmed_abstract":["<h4>Background</h4>Carcinoembryonic antigen (CEA) levels may vary with administration and discontinuation of pre-hepatectomy chemotherapy in patients undergoing resection of colorectal cancer liver metastases (CLM). The prognostic significance of these changes, termed CEA dynamics, is unclear.<h4>Patients and methods</h4>Consecutive patients undergoing hepatectomy for CLM (2001-2021) at a comprehensive cancer center were included. CEA dynamics were classified as CEA normal (CEA < 5 ng/mL before, during, and after chemotherapy), CEA decrease (elevated CEA levels that drop during and after chemotherapy), and CEA rebound (elevated CEA levels that drop during chemotherapy but rebound upon discontinuation). Recurrence-free (RFS), hepatic-specific disease-free (hDFS), and overall survival (OS) w"],"journal":["Annals of surgical oncology"],"pubmed_title":["CEA Rebound After Discontinuation of Pre-Hepatectomy Chemotherapy Predicts Worse Outcomes After Resection of Colorectal Cancer Liver Metastases."],"pmcid":["PMC11773633"],"funding_grant_id":["P30CA016672","P30 CA016672"],"pubmed_authors":["Chun YS","Maki H","Newhook TE","Vauthey JN","Tzeng CD","Haddad A","Uppal A","Tran Cao HS","Wang Y","Ayabe RI","Lendoire M","Folkert I"],"additional_accession":[]},"is_claimable":false,"name":"CEA Rebound After Discontinuation of Pre-Hepatectomy Chemotherapy Predicts Worse Outcomes After Resection of Colorectal Cancer Liver Metastases.","description":"<h4>Background</h4>Carcinoembryonic antigen (CEA) levels may vary with administration and discontinuation of pre-hepatectomy chemotherapy in patients undergoing resection of colorectal cancer liver metastases (CLM). The prognostic significance of these changes, termed CEA dynamics, is unclear.<h4>Patients and methods</h4>Consecutive patients undergoing hepatectomy for CLM (2001-2021) at a comprehensive cancer center were included. CEA dynamics were classified as CEA normal (CEA < 5 ng/mL before, during, and after chemotherapy), CEA decrease (elevated CEA levels that drop during and after chemotherapy), and CEA rebound (elevated CEA levels that drop during chemotherapy but rebound upon discontinuation). Recurrence-free (RFS), hepatic-specific disease-free (hDFS), and overall survival (OS) w","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Feb","modification":"2025-04-04T20:57:03.722Z","creation":"2025-04-04T20:57:03.722Z"},"accession":"S-EPMC11773633","cross_references":{"pubmed":["39516416"],"doi":["10.1245/s10434-024-16370-x"]}}